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Abstract
Introduction: Accumulating evidence suggests that, in critically ill patients, a lower hemoglobin transfusion
threshold is safe. However, the optimal hemoglobin level and associated transfusion threshold remain unknown in
neurocritically ill patients.
Methods: We conducted a systematic review of comparative studies (randomized and nonrandomized) to evaluate
the effect of hemoglobin levels on mortality, neurologic function, intensive care unit (ICU) and hospital length of
stay, duration of mechanical ventilation, and multiple organ failure in adult and pediatric neurocritically ill patients.
We searched MEDLINE, The Cochrane Central Register of Controlled Trials, Embase, Web of Knowledge, and Google
Scholar. Studies focusing on any neurocritical care conditions were included. Data are presented by using odds
ratios for dichotomous outcomes and mean differences for continuous outcomes.
Results: Among 4,310 retrieved records, six studies met inclusion criteria (n = 537). Four studies were conducted in
traumatic brain injury (TBI), one in subarachnoid hemorrhage (SAH), and one in a mixed population of
neurocritically ill patients. The minimal hemoglobin levels or transfusion thresholds ranged from 7 to 10 g/dl in the
lower-Hb groups and from 9.3 to 11.5 g/dl in the higher-Hb groups. Three studies had a low risk of bias, and three
had a high risk of bias. No effect was observed on mortality, duration of mechanical ventilation, or multiple organ
failure. In studies reporting on length of stay (n = 4), one reported a significant shorter ICU stay (mean, -11.4 days
(95% confidence interval, -16.1 to -6.7)), and one, a shorter hospital stay (mean, -5.7 days (-10.3 to -1.1)) in the
lower-Hb groups, whereas the other two found no significant association.
Conclusions: We found insufficient evidence to confirm or refute a difference in effect between lower- and
higher-Hb groups in neurocritically ill patients. Considering the lack of evidence regarding long-term neurologic
functional outcomes and the high risk of bias of half the studies, no recommendation can be made regarding
which hemoglobin level to target and which associated transfusion strategy (restrictive or liberal) to favor in
neurocritically ill patients.
Introduction
Anemia is highly prevalent in the intensive care unit
(ICU), with up to 95% of critically ill patients developing
subnormal hemoglobin levels by day 3 [1]. Likewise,
20% to 53% of patients receive red blood cell (RBC)
transfusions to correct anemia during their ICU stays
[2]. However, allogenic RBC transfusions carry risks that
may adversely affect clinical outcomes [3,4]. Evidence
suggests that it is safe to adopt a lower transfusion
threshold for the general medical/surgical ICU popula-
tion [1,4-8]. This has led to a paradigm shift concerning
RBC transfusions in the ICU, with most guidelines now
recommending hemoglobin levels around 7 g/dl for
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transfusion in patients without significant comorbidities
to minimize exposure to allogenic blood [9-11].
Most studies of transfusion thresholds have focused
on a general medical/surgical ICU population but not
on specific, and potentially more vulnerable, subpopula-
tions of critically ill patients, such as those with acute
neurologic conditions [12]. Indeed, neurocritically ill
patients may represent an exception to the rationale for
using low transfusion triggers because impaired oxygen
delivery is a crucial modifiable factor in brain ischemia
and secondary brain injury [13,14]. The optimal hemo-
globin level for cerebral oxygen delivery in these
patients is still unknown [15]. Moreover, data on which
clinicians have to rely in decision making is discordant,
as both anemia and RBC transfusion have been observed
to be associated with unfavorable clinical outcomes in
neurocritically ill patients [16-18].
Current guidelines for the optimal transfusion thresh-
old in neurocritical care populations are scarce, and
their recommendations are conflicting about which
threshold to favor [19,20]. Several narrative studies have
aimed to summarize the topic [15-18], but no systematic
review has been designed to address specifically the
question of transfusion thresholds in the neurocritical
population. We thus undertook a systematic review of
comparative studies to evaluate the effects of hemoglo-
bin levels and RBC transfusion strategies on clinical out-
comes in adult and pediatric neurocritically ill patients.
Materials and methods
This systematic review was designed in accordance with
the PRISMA statement for systematic reviews and meta-
analyses [21]. A study protocol was developed and fol-
lowed through every step of the review.
Search strategy
We designed a search strategy for Ovid MEDLINE (1949
to the present), the Cochrane Central Register of Con-
trolled Trials (1974 to Issue 1, 2011), as well as Embase
and Embase Classic (1974 to the present). Abstracts and
conference proceedings were searched in BIOSIS pre-
views (1926 to the present) and Web of Science (1898 to
the present), whereas the grey literature was searched by
using Google Scholar. We sought both randomized con-
trolled trials (RCTs) and comparative nonrandomized
studies, both prospective or retrospective. No restriction
based on language, year, or type of publication was
applied. Keywords and Medical Subject Headings
(MeSH) terms (or their EMTREE equivalents) pertaining
to the population (neurocritical care) and to the exposure
(hemoglobin levels, RBC transfusion, anemia) were com-
bined to form the search strategy (Additional file 1). We
used clinicaltrials.gov, controlled-trials.com, and stroke-
center.org websites to identify unpublished and ongoing
studies. Reference lists from relevant reviews and
included articles were manually searched to identify
missed studies. The last iteration of the search process
was completed on January 31, 2011.
Selection of studies
We included comparative studies evaluating the effect of
hemoglobin levels on clinical outcomes of neurocritically
ill patients admitted to an ICU. Studies were included if
at least two different hemoglobin thresholds, levels, tar-
gets, or RBC transfusion strategies were compared. Neu-
rocritical conditions encompassed but were not limited
to subarachnoid hemorrhage (SAH), stroke, traumatic
brain injury (TBI), intracerebral hemorrhage (ICH), and
any cerebral neurosurgical conditions. Studies on sickle
cell anemia and scoliosis surgery were excluded. We
also excluded studies in neonates (< 28 days), but all
other age groups were considered.
Two independent reviewers (PD, MHT) screened the
studies identified from the systematic search. Non-Eng-
lish language articles were translated as required. A
Cohen kappa statistic was calculated to quantify the
interrater agreement concerning inclusion of studies. In
case of discrepancy, a third reviewer (AFT) was involved
to settle the disagreement. Search results from Web of
Science, from grey literature sources, and from reference
lists of identified studies were reviewed and adjudicated
by a single reviewer (PD).
Data-collection process
A standardized abstraction form was developed and
tested before data collection. Data abstraction was con-
ducted independently, and in duplicate, by two reviewers
(PD, MHT). When judged necessary, missing informa-
tion was requested from corresponding authors.
The primary outcome measure was all-cause mortality
at any given time point. Secondary outcomes were neu-
rologic status (irrespective of the scale used), ICU length
of stay, hospital length of stay, duration of mechanical
ventilation, surrogate measures of brain oxygen delivery,
complications (including vasospasm and multiple organ
dysfunction score) [22], and serious adverse events
(thromboembolic events, myocardial infarction, pulmon-
ary edema or volume overload, transfusion-related acute
lung injury (TRALI), and infection). Data pertaining to
the study design were also retrieved, as well as charac-
teristics of patients that could act as confounders and
affect the outcomes of interest, including age, sex, dis-
ease severity, comorbidities, incidence of hypoxemia,
incidence of hypotension, and baseline hemoglobin.
Information on blood transfusion and the nature, tim-
ing, and frequency of co-interventions (hemodilution,
blood-conservation strategies, erythropoietin analogues,
and use of other blood products) were recorded.
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Assessment of methodologic quality and risk of bias
Two reviewers (PD, MHT) independently evaluated the
risk of bias in included studies. We used the Cochrane
Collaboration tool for assessing risk of bias in RCTs,
which was customized for the focus of the review [23].
We judged the overall risk of bias of individual studies
as low, moderate, high, or unclear [23]. Additionally, we
used the Downs and Black checklist [24] to assess the
methodologic quality of both RCTs and nonrandomized
studies. This checklist has been validated for reliability
and external validity. We put emphasis on how study
authors dealt with confounding factors mentioned ear-
lier in nonrandomized studies. The last item of the
Downs and Black checklist is an assessment of the ade-
quacy of the sample size of the study, which we per-
formed assuming a two-sided P value of 0.05, 80%
power, and a 10% relative difference for the main out-
come measure.
Statistical analysis
A meta-analytic approach was planned by using Mantel-
Haenztel random-effect models, if deemed appropriate.
We presented outcome data by using odds ratios with
95% confidence intervals. An odds ratio of less than 1
suggests a lower rate of the event among the patients
exposed to lower hemoglobin levels. Continuous data,
such as length of stay and physiologic parameters, were
reported as mean or median. We summarized continu-
ous data as mean difference with 95% confidence inter-
vals. We converted hematocrit to hemoglobin by using a
standard published equation [25] (Hb [g/dl] = Hct
[%]/3). All data were compiled in Review Manager (ver-
sion 5.0; The Cochrane Collaboration). A priori sensitiv-
ity analyses were planned to explore heterogeneity in
study findings, based on age, type of neurocritical condi-
tion, risk of bias, and presence of co-interventions.
Results
Search results
Our literature search yielded 4,310 studies from major
databases after removal of duplicate records (Figure 1).
Seven studies were deemed potentially elligible
[6,26-31], but one was excluded, as it reported only
summary data for the overall group [31]. The authors of
the latter study were contacted and confirmed that data
from each study group were unavailable. Therefore, six
studies were included (number of patients = 537)
[6,26-30]. The overall interrater agreement between
reviewers on inclusion was high (Cohen kappa = 0.80).
Discrepancies were resolved with the input of a third
reviewer on two occasions.
Data for the subgroup of neurocritically ill patients
from a previous RCT on transfusion thresholds in
pediatric ICUs were obtained from the authors for one
study [6]. Attempts to contact the authors of two
other studies to obtain data on subgroups of published
RCTs were unsuccessful [32,33]. Two abstracts of
potentially relevant studies were retrieved through the
review of conference proceedings; however, one
reported data on a study already included in our
review [29,34], whereas the other abstract [35] had not
yet been published as a full report. Additional data for
this study could not be obtained from the correspond-
ing author. Of note, one relevant ongoing study was
identified [36].
Study characteristics
Among the six studies included, three were from the
United States [28-30], two from Canada [26,28], and
one was completed in Switzerland [27] (Table 1). All
studies were published in peer-reviewed English lan-
guage journals within the last 5 years, and the period
over which the studies were conducted spanned from
1994 to 2011. Only one study involved pediatric patients
[6], whereas the other five studies took place in adult
ICUs. One study was an RCT [30], one was a subgroup
analysis of an RCT in the overall critically ill adult
population (Transfusion Requirements in Critical Care
(TRICC) trial) [26], one was an unpublished subgroup
analysis of an RCT in the critically ill pediatric popula-
tion (Transfusion Requirements in the Pediatric
Records identified through database 
searching 
(MEDLINE, EMBASE, The Cochrane Central 
Register of Controlled Trials, BIOSIS, Web of 
Science) 
(n = 4809) 
Additional records 
identified from the grey 
literature (n = 6) 
Records after duplicates removed 
(n = 4310) 
Titles and abstracts screened 
(n = 4310) 
Records excluded 
(n = 4237) 
Full-text articles assessed for eligibility 
(n = 79) 
Full-text articles excluded 
(n = 73) 
 
not NCP population n = 1 
not on Hb levels n = 37 
not comparative study n = 24 
review, editorial or comment n = 5 
abstract only* n = 1 
unavailable data* n = 2 
ongoing studies n = 1 
same patients  n = 1 
outcome not reported by 
randomization groups n=1 
*data could not be obtained from 
corresponding authors 
Studies included in qualitative synthesis 
(n = 6) 
Figure 1 Flow diagram of study selection . Hb, hemoglobin
concentration; NCP, neurocritically ill patient.
Desjardins et al. Critical Care 2012, 16:R54
http://ccforum.com/content/16/2/R54
Page 3 of 11
Intensive Care Unit (TRIPICU) trial) [6], and three were
retrospective cohort studies [27-29]. The main diagnosis
of patients was traumatic brain injury (n = 4) [26-29]
and subarachnoid hemorrhage (n = 1) [30]. The subset
data used from the TRIPICU study [6] included patients
representing different neurocritical care conditions: TBI
(n = 36), ICH (n = 11), brain tumors (n = 3), neurosur-
gery (excluding scoliosis surgery) (n = 9), cerebral
edema (n = 5) and other space-occupying injuries (n =
2).
All six studies compared two groups of patients whose
targets or observed hemoglobin levels differed, having or
having not received an RBC transfusion (Table 2). Three
studies, all of which were RCTs, described mandatory
transfusion protocols [6,26,30] based on specified hemo-
globin thresholds. Two observational studies [28,29]
compared groups of patients who received or did not
receive RBC transfusion for a specified baseline hemo-
globin range. One cohort study compared patients who
reached and did not reach a target hemoglobin level
after the resuscitation phase of TBI [27].
Among studies, lower hemoglobin levels or thresholds
ranged from 7 g/dl to 10 g/dl, whereas higher hemoglo-
bin levels or thresholds ranged from 9.3 to 11.5 g/dl.
One study divided patients on the basis of achieved
hemoglobin levels above or below 9.3 g/dl [27]. The
duration of exposure to these hemoglobin levels varied
among studies. In three of six studies [6,26,30], hemo-
globin levels were maintained during the entire ICU
stay. In the remaining three studies [27-29], hemoglobin
levels were measured at only one point in time, and
thus the exposure was not necessarily sustained. Among
the four studies [6,26,27,30] for which the mean hemo-
globin levels during the period of exposure could be
obtained, all observed a statistically significant difference
of at least 1 g/dl (range, 1.2 to 2.78 g/dl) between the
two comparison groups. The follow-up period varied
between 28 days and 6 months among studies.
Table 1 Description of included studies
















Mortality, MODS, ICULOS, HLOS,
RBCT during ICU, infection,
physician nonadherence
Age, APACHE score, use of pulmonary










Severe TBI In-hospital mortality, ICU
complications, GOSe
Worst Hct during ER/OR phase,
transfusion and volume management
during ER/OR phase, complications




















MODS, progression of MODS,















Severe TBI Mortality, pneumonia, UTI,
bacteremia, sepsis, decubitus ulcer,
myocardial infarction, seizure, DVT,
pulmonary embolus
Age, gender, motor and total GCS,
admission BAL, head and neck AIS
score, ISS, presence of SAH, min. ICU












GOSe, FSE, mortality Age, head AIS score, days with Hb <
10 g/dl, RBCT performed, volume of
RBCT, highest serum glucose, days
with serum glucose > 200 mg/dl,
HLOS, admission GCS, mild versus


















vasospasm, pulmonary edema or
respiratory distress
NIH Stroke Scale, modified Rankin
Scale
Age, WFNS score on admission,
history of hypertension or diabetes
3
months
AIS, abbreviated injury scale; APACHE, Acute Physiology and Chronic Health Evaluation; BAL, blood alcohol level; DVT, deep vein thrombosis; ER, emergency
room; FSE, functional status examination; GCS, Glasgow Coma Scale; GOSe, Extended Glasgow Outcome Scale; Hb, hemoglobin concentration; Hct, hematocrit;
HLOS, hospital length of stay; ICH, intracerebral hemorrhage; ICU, intensive care unit; ICULOS, intensive care unit length of stay; ISS, injury severity score; MODS,
multiple organ dysfunction syndrome; NIH, National Institutes of Health; NR, not reported; OR, operating room; RBCT, red blood cell transfusion; RCT, randomized
controlled trial; SAH, subarachnoid hemorrhage; TBI, traumatic brain injury; UTI, urinary tract infection; WFNS, World Federation of Neurosurgeons.
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One study reported the use of triple-H (hemodilution,
hypertension, hypervolemia) therapy in patients with
symptomatic vasospasm afer a subarachnoid hemor-
rhage [30]. The incidence of vasospasm was not signifi-
cantly different in the higher-hemoglobin and lower-
hemoglobin groups (24% and 22%, respectively; P =
1.00). The use of fresh-frozen plasma was reported in
two studies [6,28]. In one study, only two patients (one
in each group) received fresh-frozen plasma [6]; whereas
in the other, a mean of one more unit was given in the
higher-Hb group (P = 0.046) [28]. No other relevant co-
interventions susceptible to interfere with hemoglobin
levels and outcomes were documented.
Assessment of methodologic quality and risk of bias
All RCTs and subgroups of RCTs presented an overall
low risk of bias (Table 3) [6,26,30]. Given the nature of
the intervention, no study was blinded to allocation
during ICU management. All studies reported adequate
allocation concealment before and during enrollment.
Data analysis of these three studies respected the
intention-to-treat principle. Nonrandomized studies
generally were of lower methodologic quality than
RCTs and subgroup analyses of RCTs. Two of the six
studies [27,30] did not adjust study estimates for
important confounding factors, such as severity of the
baseline condition.
Table 2 Description of red blood cells transfusion strategies or hemoglobin levels compared in included studies




































NR NR Yes Threshold 10 g/dl
Target range 10-12
g/dl












Target range 7-9 g/
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NR NR 28.65 NR 12.4 NR No Hb ≥9.3 g/dl by the
end of OR phase
31 (30) 11.1 NR
Lower Hb
(n = 37)
32.70 10.4 Hb < 9.3 g/dl by










NR NR 8.2 ± 0.9 NR Yes Threshold 9.5 g/dl
Target range 11-12
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7.7 ± 1.0 Threshold 7 g/dl
Target range 8.5-9.5
g/dl













0.12 NR No Received at least 1
RBCT when Hb was
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0.663 No Received at least 1
RBCT when Hb was














RBCT when Hb was

















13.1 Threshold 10 g/dl 19 (82) 11.1 ± 0.4
GCS Glasgow Coma Scale; Hb hemoglobin concentration; ISS injury severity score; NR not reported; OR operating room; RBCT red blood cell transfusion. aMean ±
standard deviation.
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Table 3 Risk of bias and methodologic quality assessment of included studies














Bias Confounding Power Total
/11 /3 /7 /6 /5 /32
RCTs or subgroup of RCTs
McIntyre et al.
2006a
Low Low High Low Low Low Low 10 3 6 5 0 24
Lacroix et al.
2007a
Low Low High Low Low Low Low 11 3 5 6 0 25
Naidech et al.
2010




5 3 6 4 0 18
George et al.
2008
9 2 4 3 0 18
Warner et al.
2010
9 2 6 3 1 21














Given the substantial heterogeneity observed in study
designs and participants of included studies, a formal
meta-analysis was considered to be inappropriate, and
data were not pooled. Study data were therefore descrip-
tively synthesized. For the same reason, we did not
quantify statistical heterogeneity, and we did not con-
duct sensitivity analyses as planned.
Mortality
Five studies presented data on mortality [6,26-29]. None
showed a statistically significant effect of lower Hb levels
when compared with higher Hb levels (Table 4).
Neurologic outcomes
One study reported short and mid-term neurologic out-
comes, as defined by the National Institutes of Health
(NIH) Stroke Scale (14 days) and the modified Rankin
scale (14 and 28 days, and 3 months) [30], and one
study evaluated long-term (≥6 months) functional neu-
rologic outcome by using the extended Glasgow out-
come scale (GOSe) [29]. When looking at the former,
the median scores on the NIH Stroke scale were 1 (Q1
to Q3: 0 to 9.75) in the higher-Hb group versus 2 (0 to
16) in the lower-Hb group (P > 0.10). At 14 days, 13
patients in the higher-Hb group were considered “inde-
pendent” on the modified Rankin Scale as opposed to
10 in the lower-Hb group, but the difference was not
statistically significant (P = 0.25). Findings at 28 days
(14 versus 16 patients; P = 0.34) and at three months
(18 versus 20 patients; P = 1.00) were similar and did
not achieve statistical significance [30]. Compared with
a higher-Hb target group (patients transfused when Hb
was between 7 and 10 g/dl), investigators of the second
study observed a statistically significant increase in the
GOSe score (5.7 versus 3.9; P < 0.0005, higher score
meaning better outcome) at six months in patients in
the lower Hb target group (not transfused when Hb was
between 7 and 10 g/dl). This difference remained signifi-
cant after adjustment was made for the Glasgow Coma
Scale score on admission (5.4 ± 0.3 versus 4.1 ± 0.2; P =
0.0005) [29].
Duration of mechanical ventilation
Two studies [6,30] reported the duration of mechanical
ventilation and observed no significant difference in the
number of days on mechanical ventilation between the
higher and lower hemoglobin-level groups (mean differ-
ence, 0.57 days (95% CI, -1.78 to 2.92) and -0.63 days
(95% CI, -1.85 to 0.60), respectively).
Length of stay
Four of the six studies [6,26,28,29] reported length of
stay (Table 5). A significantly different mean ICU length
of stay in favor of the lower-Hb group (11.0 days) versus
the higher-Hb group (16.7 days; P = 0.02) was observed
in one study [28]. In this study, a similar effect was
observed for hospital stay, but it did not reach statistical
significance. A significant difference in mean hospital
stay was, however, observed in one study (mean differ-
ence, -11.40 (95% CI, -16.0 to -6.70)) in favor of the
lower-Hb group [29]. In contrast, results of two other
studies did not show a significant difference in ICU
length of stay between the two study groups [6,26].
Organ failure
Two studies addressed organ failure by using the multi-
ple organ dysfunction score (MODS) [6,26]. In both stu-
dies, neither the progression of organ failure nor the
emergence of a new MODS was significantly different
between the restrictive and the liberal groups. In the
subgroup of neurocritically ill patients from the TRI-
PICU study, the proportion of patients with new or wor-
sening MODS was 16.6% in the restrictive group versus
8.3% in the liberal group, but this difference did not
achieve statistical significance (P = 0.45) [6]. In the sub-
group analysis of patients with traumatic brain injury
from the TRICC trial, the worsening of MODS was also
similar in both intervention arms (3.4 restrictive versus
4.5 liberal; P = 0.49) [26].
Serious adverse events
We assessed for the reporting of myocardial infarction,
pulmonary edema and volume overload, transfusion-
related acute lung injury, thromboembolic events, and
Table 4 Effects of lower versus higher hemoglobin levels on mortality
No. of events/No. of participants
Study Time frame Lower Hb Higher Hb Odds ratio (95% CI)
McIntyre et al. 2006 30 days 5/29 5/38 1.38 [0.36, 5.29]
Flückiger et al. 2010 In-hospital 17/37 34/102 1.70 [0.79, 3.66]
Lacroix et al. 2007 28 days 2/30 1/36 2.50 [0.22, 29.01]
George et al. 2008 In-hospital 11/39 15/43 0.73 [0.29, 1.87]
Warner et al. 2010 6 months 6/63 13/76 0.51 [0.18, 1.43]
CI, confidence interval; Hb, hemoglobin concentration.
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infections (Table 6). At least one serious adverse event
was included as a secondary outcome in five studies
[6,26-28,30], but no study reported a systematic method
to screen for serious adverse events. The reported inci-
dence of adverse events is shown in Table 6.
Discussion
In this systematic review, despite our thorough search of
the literature, we identified very few comparative studies
of transfusion strategies conducted in different pediatric
or adult neurocritically ill populations. Insufficient data
exist to refute or confirm a mortality benefit associated
with the maintenance of lower or higher hemoglobin
level nor to support a consistent effect on organ failure
and duration of mechanical ventilation. A potential
decrease in hospital and ICU length of stay was
observed, but only in studies with high risk of bias.
Interestingly, only two studies presented long-term func-
tional outcomes but were not designed to evaluate a
plausible clinical effect. These results underscore the
paucity of evidence to justify the use of a restrictive or a
liberal strategy for RBC transfusions in neurocritically ill
patients.
Many theoretic effects of maintaining low hemoglobin
levels in neurocritically ill patients have been described
in previous experimental studies. Lower hemoglobin
concentration is directly related to lower blood viscosity
[37]. In mild anemia, this decrease in viscosity causes an
increase in cerebral blood flow (CBF) through a direct
rheologic effect and improves cerebral oxygen delivery
(DO2) [38]. However, more-severe anemia may be detri-
mental in neurocritically ill patients because the decline
in CaO2 may not be compensated by the usual CBF reg-
ulation mechanisms, which are mitigated in brain injury.
On clinical grounds, anemia has repeatedly been shown
to be associated with unfavorable outcomes in patients
with TBI [39,40], although other studies have not con-
firmed this relation [41,42]. In patients with SAH, ane-
mia has mostly been associated with unfavorable
outcomes [43-45]. Recent microdialysis studies showed
that cerebral metabolism becomes impaired at Hb values
lower than 9 g/dl [46,47].
RBC transfusions are known to improve physiologic
measures such as brain oxygen tension in a majority of
patients with TBI [31,48-50]. Retrospective cohort stu-
dies in patients with SAH reported an association
between the correction of anemia with RBC transfusion
and unfavorable outcomes [51,52], more complications
[53], and vasospasm [54]. Both anemia and RBC transfu-
sion have thus been associated with worse clinical out-
comes in different neurocritically ill patients.
Interestingly, we did not observe similar findings in
our study. This is likely to be explained by the fact that
we studied the impact of the exposure to Hb levels and
transfusion strategies on outcomes, unlike most previous
studies, which evaluated the impact of RBC transfusions
(as a risk factor for a specific oucome measure rather
than an intervention), regardless of the hemoglobin
thresholds or Hb levels. By doing so, we aimed to avoid
two potential biases. The first pertains to anemia, which
Table 6 Reported adverse events
Study Number of patients with adverse events
Myocardial infarction Pulmonary edema/volume
overload
TRALI Thromboembolism Infections
Lower Hb Higher Hb Lower Hb Higher Hb Lower Hb Higher Hb Lower Hb Higher Hb Lower Hb Higher Hb
McIntyre et al. NR NR NR NR NR NR NR NR 2 2
Flückiger et al. NR NR NR NR NR NR NR NR NR NR
Lacroix et al. NR NR NR NR NR NR NR NR 10 14
George et al. 1 0 NR NR NR NR 2 10 2 1
Warner et al. NR NR NR NR NR NR NR NR NR NR
Naidech et al. NR NR 8 3 NR NR NR NR 2 2
Hb, hemoglobin concentration; NR, not reported; TRALI, transfusion-related acute lung injury.
Table 5 Effects of lower versus higher hemoglobin levels on length of stay
Study Time frame Measure Lower Hb Higher Hb P value Mean difference (95% CI)
McIntyre et al. 2006 ICU Median (IQ range) 10 (5-21) 8 (5-11) 0.26 Not estimable
Hospital 27 (14-39) 30.5 (17-47) 0.72
Lacroix et al. 2007 ICU Mean (± SD) 8.0 ± 5.2 9.9 ± 7.0 0.37 -1.9 [-4.9, 1.1]
George et al. 2008 ICU Mean (± SD) 11.0 ± 8.6 16.7 ± 12.2 0.02 -5.7 [-10.3, -1.1]
Hospital 13.0 ± 9.9 17.7 ± 11.7 0.09 -4.7 [-9.4, 0.02]
Warner et al. 2010 Hospital Mean (± SD) 11.7 ± 7.4 23.1 ± 17.8 < 0.0005 -11.4 [-16.1, -6.7]
CI, confidence interval; Hb, hemoglobin concentration; ICU, intensive care unit; IQ, interquartile; SD, standard deviation.
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often occurs in sicker patients along with confounding
variables such as a greater volume of sampled blood in
patients with more severe diseases [48]. Thus, it is
prone to confounding despite adjustment for disease
severity. The second is a potential multicolinearity bias
concerning RBC transfusion and anemia. These two
variables are strongly linked, given that anemic patients
are predisposed to receive more RBC transfusions
because of the natural tendency of physicians to give
transfusions to sicker patients. To separate the respec-
tive effects of anemia and RBC transfusion, we opted to
focus on differential transfusion strategies. Therefore,
our approach aimed to determine a potential inflexion
point (typically the mean of a hemoglobin threshold for
transfusion) at which the benefits of correcting anemia
surpass the detrimental effects of RBC transfusion.
One of the main limitations of our study pertains to
the significant inconsistency in observed summary
estimates. This may in part be due to the heterogene-
ity in study designs. Outcomes were assessed at var-
ious time points, and the exposure to Hb levels varied
across studies. In particular, the overlaping of ranges
between lower and higher Hb levels in various study
groups limited direct comparison between studies.
Moreover, the presence of a mandatory transfusion
protocol in RCTs versus the passive observation of
different hemoglobin levels in nonrandomized studies
can lead to a difference in observed effects. It would
be misleading to liken the data obtained from the
nonrandomized studies to transfusion strategies.
Accordingly, we did not pool results from RCTs and
nonrandomized studies to avoid generating a more-
precise but biased pooled estimate [23]. Still, we
believe the comparison within each trial between
groups of higher and lower Hb levels, whether by a
definite transfusion trigger or by observed exposure to
different Hb levels, is valid.
Some other concerns may affect our findings. The first
one is obviously the scarcity of RCTs in this neurocriti-
cally ill population, despite the large number of retro-
spective studies in this field. The retrieved studies are
mainly in the TBI population, with only two of the six
studies focusing on the non-TBI population. Therefore,
we cannot extrapolate our findings to stroke and ICH.
Second, most included studies were underpowered to
evaluate clinically significant outcomes, making the
detection of a difference in these outcomes unlikely, if
present. Wide confidence intervals around estimates
also stem from small sample sizes.
Third, lack of data on many relevant outcomes, such
as long-term neurologic functional status or organ dys-
function, precluded the pooling of data. Even more wor-
rying is the lack of systematic reporting of adverse
events associated with RBC transfusion, because one of
the main reasons to withhold RBC transfusion is to pre-
vent, at least theoretically, these adverse events.
Finally, the methodologic quality of three of the six
included studies was not optimal, although RCTs were
considered to have a low risk of bias. In particular,
issues with blinding and confounding cast a shadow on
the robustness of findings.
Conclusions
In our study, we could not refute or confirm a difference
in mortality or long-term neurologic outcomes between
RBC transfusion strategies in neurocritically ill patients.
Considering the lack of evidence regarding these clini-
cally significant outcomes and the risk of bias of studies,
no recommendation can be made about which transfu-
sion strategy to favor in neurocritically ill patients; no
evidence exists that maintenance of a lower or a higher
hemoglobin level is superior in this specific population.
Interestingly, despite how common RBC transfusions can
be in neurocritically ill patients, there is a paucity of evi-
dence about when it is appropriate to transfuse.
Ultimately, our findings suggest that research in trans-
fusion therapy in neurocritical care is still in its infancy.
Future research on the management of anemia and RBC
therapy is warranted. We believe such research should
assess long-term neurologic functional status, thor-
oughly seek adverse events, and encompass different
neurocritically ill populations, such as traumatic brain
injury, subarachnoid hemorrhage, and stroke.
Key messages
• Very few comparative studies have been conducted
on the effect of restrictive versus liberal RBC-trans-
fusion strategies in neurocritically ill patients. These
studies are of variable methodologic quality, and
most of them did not evaluate long-term functional
outcomes.
• Insufficient evidence exists to refute or confirm a
mortality benefit associated with the maintence of
low (restrictive) or high (liberal) hemoglobin levels
on the incidence of organ failure or on the duration
of mechanical ventilation.
• We observed a potential decrease in hospital and
ICU length of stay associated with lower-Hb levels
exposures.
• Our systematic review underscores the paucity of
evidence regarding the use of a restrictive or a liberal
strategy for RBC transfusions in neurocritically ill
patients.
Additional material
Additional file 1: OVID MEDLINE search strategy. Search strategy
used in MEDLINE (Ovid) using keywords and Medical Subject Headings
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(MeSH) terms pertaining to the population (neurocritical care) and to the
exposure (hemoglobin levels, RBC transfusion, anemia).
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